TNFRSF8 and neutropenia: In the ECHELON-1 trial, brentuximab vedotin, an anti-CD30 conjugate, was compared to ABVD when added to AVD (A + AVD), showing higher rates of neutropenia, especially in patients aged > 60 years [41].